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Background: The aim of the present study was to estimate hepatitis B virus seroprevalence among first-time blood
donors in the city of Campo Grande, Mato Grosso do Sul State, in the central-western region of Brazil.
Findings: A retrospective analysis of first-time voluntary blood donor records, from January 2010 to December
2010, was conducted at the Hematology Center of Mato Grosso do Sul. The prevalence of the HBsAg and anti-HBc
serological markers and their respective 95% confidence intervals were calculated. Chi-square analysis was
performed between the seroprevalence previously found in 2001 and the one determined by the current study.
Results were considered statistically significant if p < 0.05. Among 8,840 subjects, 269 (3.04%, 95% CI: 2.7-3.4) were
positive for HBV markers. The prevalence rate of HBsAg was 0.19% (95% CI: 0.1-0.3) and anti-HBc alone was 2.85%
(95% CI: 2.5-3.2).
Conclusions: There was no statistically significant difference regarding gender. However, an important association
was observed between HBV infection and older age (p < 0.01). The seroprevalence of HBV infection in first-time
blood donors diminished from 2001 to 2010 (p < 0.01). Such decrease suggests an improvement in the recruitment
of safe donors, the positive impact of vaccination programs and the decreasing of HBV infection prevalence in the
general population.
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Hepatitis B is one of the most common infectious di-
seases throughout the globe and has infected two billion
people, including an estimated 350 million chronically
infected cases [1,2].
Parenteral exposure has been shown to be associated
with hepatitis B virus (HBV) infection. Blood transfu-
sions carry the risk of transfusion-transmitted infections
such as hepatitis B and C. In order to measure their se-
verity, the World Health Organization has recommen-
ded a pre-transfusion blood test. The residual risk of
infection from HBV is higher than that of hepatitis C
virus (HCV) in non-endemic countries [3].
In 1971, hepatitis B surface antigen (HBsAg) test was
introduced for screening blood donors, and after 1986,
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distribution, and reproduction in any mediumwere implemented to further reduce the risk of infec-
tious agents in the blood supply [4].
The prevalence of infection in the general population
varies in different regions of the world. Although Brazil
is considered a low endemic country, there are areas that
are highly endemic for HBV in the Amazon region [5].
In Brazil, among blood donors, the prevalence ranges
from 0.3% to 1.5% for HBsAg and from 3.7% to 11.1%
for anti-HBc [4,6,7].
The aim of the present study was to estimate the sero-
prevalence of HBV infection among first-time blood do-
nors in the city of Campo Grande, the capital city of the
state of Mato Grosso do Sul, in the central-western re-
gion of Brazil.
A retrospective analysis of blood donor data from
January 2010 to December 2010 was conducted in the
Hematology Center of Mato Grosso do Sul (HEMOSUL).
People who attended the center voluntarily for their first
blood donation were selected by the standard criteria
for healthy blood donors after answering a standardizedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 2 Difference in the prevalence of hepatitis B viral
infection among first-time blood donors between 2001
and 2010, Campo Grande, Brazil
Variable HBV % Odds ratio p
Year Positive/Total (95% CI)
2001* 52/552 9.42 3.31 (2.40-4.57) < 0.01
2010 269/8,840 3.04
*Aguiar et al. [9].
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blood donor was defined as a donor who donated for the
first and only time. The protocol used in the present study
was approved by the Ethics Committee of the Federal
University of Mato Grosso do Sul.
Blood donor samples were screened for the presence
of HBsAg and total anti-HBc by enzyme-linked immu-
nosorbent assays (ELISA) (bioMérieux, Netherlands).
Positive samples were retested using the same serolo-
gical assay.
The prevalence of the HBsAg and anti-HBc serological
markers and their respective 95% confidence intervals
(95% CI) were determined. Chi-square analysis was per-
formed between the seroprevalence published in 2001
and seroprevalence found in this study (2010) and was
considered statistically significant if p < 0.05.
A total of 8,840 first-time blood donors aged between
18 to 65 years, who were considered healthy individuals
and eligible for blood donation, participated in this
study. The majority of individuals were males (60.6%,
n = 5,358) between 18 and 39 years old (81.2%,
n = 7,074), representing typical characteristics of blood
donors in Brazil. Among the 8,840 subjects, 269 (3.04%,
95% CI: 2.7-3.4) were positive for HBV markers. The
prevalence rate of HBsAg was 0.19% (95% CI: 0.1-0.3)
and anti-HBc alone was 2.85% (95% CI: 2.5-3.2). There
was no statistically significant difference with respect to
gender. A significant association was observed between
HBV infection and older age (p < 0.01) (Table 1).
As shown in Table 2, the seroprevalence of HBV infec-
tion in first-time blood donors was reduced significantly
from 2001 to 2010 (p < 0.01).
Despite the decreasing of the global HBV infection,
the use of serological markers for blood donor screen-
ings is still important, since HBV remains a great risk
for blood transfusion patients [3,8]. In this study, the
prevalence of HBV infection was 3.04% (95% CI: 2.7-3.4)
and 0.19% (95% CI: 0.1-0.3) for total anti-HBc and HBsAg,Table 1 Prevalence of hepatitis B viral infection among
first-time blood donors by gender and age in Campo
Grande, Brazil, 2010
Variable HBV % Odds ratio p
Positive/Total (95% CI)
Gender
Female 107/3,482 3.07 1.0
Male 162/5,358 3.02 0.98 (0.76-1.27) 0.94
Age (years)
18-28 99/4,990 1.98 1.0
29-39 75/2,258 3.32 1.70 (1.24-2.33) < 0.01
40-50 61/1,130 5.40 2.82 (2.01-3.95) < 0.01
51-66 34/462 7.36 3.92 (2.57-5.97) < 0.01respectively, suggesting the presence of HBV infection in
first-time blood donors. However, this is a significant drop
compared to 9.42% for total anti-HBc and 0.72% for
HBsAg prevalence rate reported by Aguiar et al. [9].
Considering that HBV infection prevalence in blood
donors depends on several factors, including the pre-
valence of the virus in the general population and the
sensitivity of screening tests, it is reasonable to assume
that the observed decline may have been due to the im-
plementation of safety measures. Particularly because
the screening tests used over the past decade were of
similar sensitivity and performed in the same laboratory
(Hemorrede Laboratory of Mato Grosso do Sul) with
similar technical capabilities.
The cause of such declined rates is multifactorial and
most likely due to the increase in vaccination programs
conducted in the general population, implementation of
a national strategy for blood safety and better data qua-
lity. Although over the past few years several studies
have shown a decreasing trend of HBV seroprevalence
among blood donors, others have found opposite results
[10-16]. According to Niederhauser [17], immunization
campaigns are efficient in reducing the risk of transfusion-
transmitted HBV.
During the last four decades, blood donor profiles
have changed as a result of the implementation of HBV
screening, which has steadily reduced the risk of trans-
mitting the virus through blood transfusion [18]. More-
over, there is a cumulative effect of increasing public
health awareness [19]. In the population-based multicen-
tric survey of hepatitis B infection in central-west Brazil,
the prevalence of HBV rates classify the region as low
endemic, rather than intermediate endemic as defined
by previous studies [5]. Such drop may be the expla-
nation for the lower seroprevalence of HBV infection
among blood donors than found by Aguiar et al. [9].
Significant increase in the seroprevalence of HBV was
observed among older people. The lower prevalence
among donors under 30 years old could be associated
with hepatitis B vaccination program, which was initi-
ated at the beginning of the 1990s in Brazil. Moreover,
higher prevalence among older donors indicates a longer
time of viral exposure, as corroborated by O’Brien et al.
[20], Nkrumah et al. [13] and Seo et al. [21].
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HBV infection prevalence according to gender. This
finding is similar to those found by Japhet et al. [22],
Nascimento et al. [6] and Ataallah et al. [23].
Our results demonstrate the importance of updated
information on HBV prevalence. The significant de-
crease of HBV infection between 2001 and 2010 among
first-time blood donors suggests an improvement in the
recruitment of safer donors, the positive impact of vac-
cination programs and the drop of HBV infection preva-
lence in the general population. This is a welcoming
result since the safety of blood products also brings be-
nefits to the general population and guides new preven-
tion strategies.
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